Yon Ho Choe Selected Research

Azathioprine (Imuran)

11/2022	Discontinuation of Azathioprine could be considered in pediatric patients with Crohn's disease who have sustained clinical and deep remission.
1/2022	NUDT15 intermediate metabolisers are associated with lower loss of response in paediatric Crohn's disease patients treated by combination treatment with infliximab and azathioprine.
1/2020	Adjustment of azathioprine dose should be based on a lower 6-TGN target level to avoid leucopenia in NUDT15 intermediate metabolisers.
5/2018	Subtherapeutic Infliximab Trough Levels and Complete Mucosal Healing Are Associated With Sustained Clinical Remission After Infliximab Cessation in Paediatric-onset Crohn's Disease Patients Treated With Combined Immunosuppressive Therapy.
12/2015	Impact of Genetic Polymorphisms on 6-Thioguanine Nucleotide Levels and Toxicity in Pediatric Patients with IBD Treated with Azathioprine.
11/2014	Safe azathioprine treatment in a pediatric ulcerative colitis patient with TPMT*16 by thiopurine metabolite monitoring.
9/2014	Monitoring thiopurine metabolites in korean pediatric patients with inflammatory bowel disease.
11/2013	Successful azathioprine treatment with metabolite monitoring in a pediatric inflammatory bowel disease patient homozygous for TPMT*3C.
9/2013	Adverse events associated with azathioprine treatment in korean pediatric inflammatory bowel disease patients.
6/2013	Monitoring and safety of azathioprine therapy in inflammatory bowel disease.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yon Ho Choe Research Topics

Disease

23	Crohn Disease (Crohn's Disease) 11/2022 - 09/2010
11	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2021 - 12/2011
9	Pediatric Crohn's disease 01/2022 - 04/2010
7	Infections 06/2017 - 08/2003
7	Prader-Willi Syndrome (Syndrome, Prader-Willi) 03/2011 - 08/2004
3	Ulcerative Colitis 07/2021 - 12/2011
3	Hyperplasia 06/2020 - 01/2009
3	Gastritis 08/2004 - 06/2002
2	Non-alcoholic Fatty Liver Disease 01/2022 - 01/2021
2	Inflammation (Inflammations) 01/2022 - 11/2019
2	Abdominal Pain (Pain, Abdominal) 09/2021 - 08/2007
2	Obesity 01/2021 - 06/2007
2	Glycogen Storage Disease (Glycogenosis) 10/2018 - 01/2007
2	Hepatomegaly 04/2016 - 12/2014
2	Leukopenia 05/2015 - 09/2013
2	Pediatric ulcerative colitis 11/2014 - 03/2014
2	Disease Progression 03/2014 - 05/2013
2	Hypersensitivity (Allergy) 05/2013 - 12/2011
2	Liver Failure 01/2013 - 04/2012
2	Sweet Syndrome (Acute Febrile Neutrophilic Dermatosis) 12/2011 - 12/2010
2	Overweight 03/2011 - 05/2006
2	Iron-Deficiency Anemia (Anemia, Iron Deficiency) 02/2009 - 08/2003
2	Insulin Resistance 04/2007 - 05/2006
1	Intussusception 07/2022
1	Gastric Outlet Obstruction 10/2021
1	Vomiting 09/2021
1	Body Weight (Weight, Body) 01/2021
1	Lymphangiectasis 01/2021
1	Neutropenia 06/2020
1	Stomatitis 06/2020
1	Agammaglobulinemia (Hypogammaglobulinemia) 06/2020
1	Myalgia 05/2020
1	Hepatic Encephalopathy 01/2019
1	Liver Diseases (Liver Disease) 10/2018
1	Glycogen Storage Disease Type Ix 04/2016
1	Mycoplasma Pneumonia 03/2016
1	Stroke (Strokes) 03/2016
1	Alagille Syndrome (Alagille-Watson Syndrome) 01/2016
1	Biliary Atresia 01/2016
1	Lymphopenia (Lymphocytopenia) 05/2015

Drug/Important Bio-Agent (IBA)

23	Infliximab (Remicade)FDA Link 01/2022 - 04/2010
13	Azathioprine (Imuran)FDA LinkGeneric 11/2022 - 12/2010
9	GhrelinIBA 05/2010 - 08/2004
6	Pharmaceutical PreparationsIBA 01/2022 - 12/2010
5	Glucose (Dextrose)FDA LinkGeneric 03/2011 - 05/2006
4	Biomarkers (Surrogate Marker)IBA 01/2022 - 11/2019
4	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2022 - 01/2018
4	AntibodiesIBA 06/2017 - 09/2015
4	Insulin (Novolin)FDA Link 03/2011 - 05/2006
3	Adalimumab (Humira)FDA Link 01/2021 - 06/2016
3	SteroidsIBA 05/2020 - 12/2012
3	Phenobarbital (Luminal)FDA Link 02/2019 - 11/2016
3	2-mercaptopurineIBA 12/2015 - 09/2014
3	Hormones (Hormone)IBA 01/2009 - 09/2005
2	AlbuminsIBA 01/2022 - 11/2019
2	Biological ProductsIBA 01/2022 - 01/2018
2	Sirolimus (Rapamycin)FDA Link 01/2021 - 06/2020
2	6-thioguanylic acidIBA 01/2020 - 09/2014
2	thiopurine methyltransferase (thiopurine S-methyltransferase)IBA 01/2020 - 09/2014
2	Immunoglobulin G (IgG)IBA 06/2017 - 03/2016
2	Proton Pump InhibitorsIBA 01/2012 - 01/2011
2	IronIBA 02/2009 - 07/2004
2	AntralIBA 08/2004 - 06/2002
1	GlobulinsIBA 01/2022
1	Leukocyte L1 Antigen Complex (Calgranulin)IBA 01/2022
1	Ustekinumab (CNTO 1275)FDA Link 01/2022
1	Interleukin-6 (Interleukin 6)IBA 01/2022
1	AntiemeticsIBA 09/2021
1	Parasympatholytics (Antispasmodics)IBA 09/2021
1	EnzymesIBA 01/2021
1	Hemoglobins (Hemoglobin)IBA 01/2021
1	LipidsIBA 01/2021
1	Octreotide (Sandostatin)FDA LinkGeneric 01/2021
1	CreatinineIBA 06/2020
1	Cyclosporine (Ciclosporin)FDA LinkGeneric 05/2020
1	CateninsIBA 11/2019
1	C-Reactive ProteinIBA 11/2019
1	Therapeutic UsesIBA 01/2019
1	1,4-alpha-Glucan Branching Enzyme (Glycogen Branching Enzyme)IBA 10/2018
1	Adrenal Cortex Hormones (Corticosteroids)IBA 05/2018
1	Monoclonal AntibodiesIBA 01/2018
1	CT-P13IBA 01/2018
1	Biosimilar PharmaceuticalsIBA 01/2018
1	Alanine Transaminase (SGPT)IBA 04/2016
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 04/2016
1	fibrin fragment D (D-dimer)IBA 03/2016
1	Fibrinogen (Factor I)FDA Link 03/2016
1	Immunoglobulins (Immunoglobulin)IBA 05/2015
1	MucinsIBA 05/2015
1	DefensinsIBA 05/2015
1	Forkhead Transcription Factors (Forkhead Box Proteins)IBA 05/2015
1	Mesalamine (Mesalazine)FDA LinkGeneric 05/2015
1	Transaminases (Aminotransferases)IBA 12/2014

Therapy/Procedure

17	Therapeutics 01/2022 - 12/2006
6	Liver Transplantation 01/2019 - 01/2007
4	Transplantation 05/2013 - 01/2007
2	Activities of Daily Living (ADL) 01/2021 - 04/2020
2	Ligation 01/2019 - 11/2013
1	Enema (Enemas) 07/2022
1	Transitional Care 01/2021